cholesterol lowering intervention

Atorvastatin - Bezafibrate - Cerivastatin - Cholestyramine - Clofibrate - Colestipol - Diet - Etofibrate - Ezetimibe - Fenofibrate - Fluvastatin - Gemfibrozil - Lovastatin - Niacin - Policosanol - Pravastatin - Probucol - Rosuvastatin - Simvastatin      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathnon cardiovascular death

acute coronary syndrome

atorvastatin
MIRACL, 2001     atorvastatinplaceboacute coronary syndrome early initiation Low risk of bias suggesting-5%
Colivicchi, 2002     atorvastatinusual careacute coronary syndrome early initiation Exploratory negative-23%
ESTABLISH, 2004     atorvastatinusual careacute coronary syndrome early initiation Exploratory negative-100%
PROVE IT - TIMI 22, 2004     atorvastatinpravastatinacute coronary syndrome early initiation Low risk of bias suggesting-28%
ezetimibe
IMPROVE-IT, 2014      NCTezetimibeplacebo (on top statins) early initiation Low risk of bias conclusive-1%
fluvastatin
LIPS (sub groups), 2002     fluvastatinplaceboacute coronary syndrome early initiation Low risk of bias negative-27%
FLORIDA, 2002     fluvastatinplaceboacute coronary syndrome early initiation Low risk of bias negative-34%
pravastatin
LAMIL, 1997   pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
RECIFE, 1999     pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
PAIS, 2001   pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
PACT, 2004     pravastatinplaceboacute coronary syndrome early initiation Low risk of bias suggesting-31%
L-CAD, 2000     pravastatinusual careacute coronary syndrome early initiation Exploratory suggesting-20%
PTT, 2002   pravastatinusual careacute coronary syndrome early initiation Exploratory suggesting
simvastatin
A to Z, 2004     simvastatinplaceboacute coronary syndrome early initiation negative-10%

acute myocardial infarction

atorvastatin
PROVE-IT, 2004         atorvastatin high dosepravastatindiabetic early initiation Low risk of bias suggesting

aortic stenosis

atorvastatin
SALTIRE, 2005     atorvastatinplaceboaortic stenosisLow risk of bias negative
rosuvastatin
ASTRONOMER, 2010   rosuvastatinplaceboaortic stenosisLow risk of bias -
simvastatin
SEAS, 2008    NCTezetimibe+simvastatinplaceboaortic stenosisLow risk of bias negative

CABG surgery

atorvastatin
Chello et al., 2006     preoperative atorvastatinplaceboLow risk of bias negative
Patti et al., 2006     preoperative atorvastatinplaceboLow risk of bias suggesting-2%
simvastatin
Christenson, 1999     preoperative simvastatinno treatmentnegative

cardiovascular prevention

atorvastatin
ASCOT (diabetics sub group), 2003   atorvastatinplacebodiabetic patients primary prevention Exploratory negative
CARDS, 2004      NCTatorvastatinplacebodiabetic type 2 diabetes Low risk of bias conclusive-26%
Deutsche Diabetes Dialyse Studie (4D), 2005   atorvastatinplaceboLow risk of bias suggesting-5%-3%
ASPEN, 2006     atorvastatinplacebodiabetic type 2 diabetes Low risk of bias negative
ASPEN, 2006     atorvastatinplacebodiabetic patientsLow risk of bias negative2%
ASCOT, 2003   atorvastatinplaceboat risk hypertensive hypertensive patients Low risk of bias conclusive-13%-15%
MIRACL, 2001     atorvastatinplaceboacute coronary syndrome early initiation Low risk of bias suggesting-5%
macin, 2005     atorvastatinplaceboacute coronary syndrome squamous NSCLC Low risk of bias -
SALTIRE, 2005     atorvastatinplaceboaortic stenosisLow risk of bias negative
Mohler III, 2003   atorvastatinplaceboPeripheral Arterial DiseaseExploratory -
SPARCL, 2006      NCTatorvastatinplacebopost stroke cerebral vascular disease Low risk of bias suggesting2%
Strey, 2005     atorvastatinplaceboheart failure -
Mohler, 2003     atorvastatinplacebosecondary preventionLow risk of bias -
ASPEN (primary prevention sub group), 2006     atorvastatinplacebodiabetic type 2 diabetes Low risk of bias negative6%-10%
ASCOT (women subgroup) , 2003     AtorvastatinplacebowomenExploratory negative
Colivicchi, 2002     atorvastatinusual careacute coronary syndrome early initiation Exploratory negative-23%
ESTABLISH, 2004     atorvastatinusual careacute coronary syndrome early initiation Exploratory negative-100%
GREACE, 2002     atorvastatinusual caresecondary preventionRisk of bias suggesting-43%50%
AVERT, 1999     atorvastatin high doseangioplastysecondary preventionRisk of bias negative
TNT (diabetic sub group), 2006     atorvastatin high doseatorvastatindiabetic patients secondary prevention Low risk of bias suggesting10%
TNT, 2005            NCTatorvastatin high doseatorvastatinsecondary preventionLow risk of bias conclusive 1%
Vascular basis, 2005     atorvastatin high doselovastatinsecondary preventionExploratory negative+Infini%
PROVE IT - TIMI 22, 2004     atorvastatinpravastatinacute coronary syndrome early initiation Low risk of bias suggesting-28%
REVERSAL, 2004     atorvastatin high dosepravastatinsecondary preventionExploratory negative
PROVE-IT, 2004         atorvastatin high dosepravastatindiabetic early initiation Low risk of bias suggesting
SAGE, 2007     atorvastatin high dosepravastatinsecondary preventionExploratory suggesting-67%-67%
IDEAL, 2005        NCTatorvastatin high dosesimvastatinsecondary preventionRisk of bias suggesting -2%
bezafibrate
SENDCAP, 1998     bezafibrateplacebo type 2 diabetes Exploratory suggesting-100%
LEADER, 2002     bezafibrateplaceboLow risk of bias negative5%
LEADER trial, 2000   bezafibrateplaceboPeripheral Arterial DiseaseLow risk of bias -
BECAIT, 1996     bezafibrateplacebosecondary preventionExploratory suggesting+Infini%
BIP, 2000       bezafibrateplacebosecondary preventionLow risk of bias negative6%3%
cerivastatin
Laufs, 2004     cerivastatinplaceboheart failureLow risk of bias -
cholestyramine
STARS (cholestyramine), 1992     cholestyraminecontrolLow risk of bias negative-100%
LRC, 1984   cholestyramineplaceboLow risk of bias negative-5%15%
NHLBI (Brensike), 1984    NCTcholestyramineplacebodiabeticExploratory negative-28%-100%
clofibrate
WHO clofibrate, 1978   clofibrateplaceboLow risk of bias suggesting 27%41%
Cullen, 1974   clofibrateplaceboLow risk of bias -
Harrold, 1969   clofibrateplacebo type 2 diabetes Low risk of bias -
Hanefeld, 1991   clofibrateplacebo type 2 diabetes Low risk of bias negative
Begg, 1971   clofibrateplacebosecondary preventionExploratory negative-58%
Acheson, 1972   clofibrateplacebosecondary prevention cerebral vascular disease Exploratory -
VA Neurology Section, 1974   clofibrateplaceboLow risk of bias -
CDP Clofibrate, 1975   clofibrateplaceboLow risk of bias suggesting -2%55%
Scottish, 1971   clofibrateplaceboLow risk of bias negative-2%-16%
Newcastle, 1971   clofibrateplaceboLow risk of bias suggesting-37%-11%
SCOR, 1990     colestipol+clofibrateplacebodiabeticLow risk of bias negative-100%-100%
colestipol
UCS (Dorr), 1978   colestipolplaceboLow risk of bias negative-24%5%
Ryan, 1974   colestipolplaceboLow risk of bias -
Gundersen, 1976   colestipolplaceboLow risk of bias -
Ruoff, 1978   colestipolplaceboLow risk of bias negative-100%
Gross, 1973   colestipolplaceboLow risk of bias -
diet
Veterans Ad. (Dayton), 1969   dietusual dietLow risk of bias suggesting -2%
MRFIT, 1982   dietusual dietRisk of bias -
Hjermann, 1981   dietusual dietRisk of bias -
Finnish Mental Hospital (Miettinen), 1985     dietusual dietprimary preventionExploratory -
WHO Collaborative, 1986   dietusual dietLow risk of bias negative-1%1%
Goteborg, 1986     dietusual dietRisk of bias -
Rose, 1965   dietusual dietExploratory negative285%
Singh, 1992   dietusual dietRisk of bias -
STARS (St Thomas, diet), 1992     dietusual dietExploratory negative-67%
Los Angeles VA (Dayton), 1969   dietusual dietLow risk of bias -
Ornish, 1990     dietusual dietExploratory negative+Infini%
Kallio, 1979   dietusual dietExploratory -
MRC Soya, 1968   dietusual dietRisk of bias negative-12%-84%
Woodhill, 1966   dietusual dietLow risk of bias negative49%114%
Oslo Diet Heart Study (Leren), 1966   dietusual dietRisk of bias suggesting-25%-20%
MRC low fat, 1965   dietusual dietRisk of bias negative-13%
WHI low fat, 2005    NCTdietusual dietExploratory negative
Göteborg (Wilhelmsen), 1986     dietusual dietLow risk of bias negative-2%-2%
Black, 1994     dietusual dietRisk of bias negative-51%+Infini%
Minnesota coronary survey (Frantz), 1975   dietusual dietExploratory negative3%
Tuttle, 2008     low fat dietmediterranean-style dietRisk of bias -
estrogen
Marmorstein, 1962   estrogenplaceboLow risk of bias -
Stamler, 1963   estrogenplaceboLow risk of bias -
CDP estrogen 5, 1975   estrogenplaceboLow risk of bias -
CDP estrogen 2.5, 1975   estrogenplaceboLow risk of bias -
VA Neurology Section (estrogen), 1966   estrogenplaceboLow risk of bias -
VA drugs (Estrogen or thyroxine), 1968   estrogen or thyroxineplaceboLow risk of bias suggesting-61%-57%
etofibrate
Emmerich, 2009     etofibrateplacebodiabetic type 2 diabetes Exploratory -
ezetimibe
SHARP, 2010      NCTezetimibe+simvastatinplaceboLow risk of bias suggesting2%
IMPROVE-IT, 2014      NCTezetimibeplacebo (on top statins) early initiation Low risk of bias conclusive-1%
Enhance, 2008   ezetimibeplacebo (on top statins)Low risk of bias -
SANDS, 2008      NCTaggressive treatmentstandard teatmentdiabetic type 2 diabetes Exploratory negative-51%
ARBITER-HALTS 6, 2010   ezetimibeniacinExploratory -
fenofibrate
FIELD, 2005     fenofibrateplacebodiabetic patientsLow risk of bias suggesting10%
DAIS, 2001     fenofibrateplacebodiabetic type 2 diabetes Exploratory negative-32%-49%
FIELD, 2005             fenofibrateplacebodiabetic type 2 diabetes Low risk of bias suggesting 10%
ACCORD lipid, 2010    NCTfenofibrateplacebo (on top simvastatine)diabetic patientsLow risk of bias negative-9%
fluvastatin
LIPS (diabetic sub group), 2002     fluvastatinplacebodiabetic patients secondary prevention Exploratory suggesting
ALERT (diabetic sub group), 2003     fluvastatinplacebodiabetic patientsLow risk of bias -
FLARE (elderly subgroup), 1999       fluvastatinplaceboelderly elderly Low risk of bias negative-65%
LIPS (elderly subgroup), 2002     fluvastatinplaceboelderly elderly Low risk of bias suggesting-34%
LIPS (sub groups), 2002     fluvastatinplaceboacute coronary syndrome early initiation Low risk of bias negative-27%
FLORIDA, 2002     fluvastatinplaceboacute coronary syndrome early initiation Low risk of bias negative-34%
LCAS, 1997     fluvastatinplacebosecondary preventionExploratory negative-4%-36%
Riegger et al., 1999     fluvastatinplacebosecondary preventionLow risk of bias negative-52%
FLARE, 1999     fluvastatinplacebosecondary preventionExploratory negative-55%
BCAPS, 2001     fluvastatinplaceboprimary prevention cerebral vascular disease Low risk of bias